2017 Press Releases

Keyword Search
 
2017 | 2016
DateTitle 
03/14/17Pulse Biosciences Quartery Investor Conference Call
Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif.--(BUSINESS WIRE)--Mar. 14, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), is hosting an investor conference call today to share information on recent developments and progress for its novel NPS platform in key markets. The Company will also ... 
Printer Friendly Version
03/14/17Pulse Biosciences Submits 510(k) Application to FDA for PulseTx™ System
BURLINGAME, Calif.--(BUSINESS WIRE)--Mar. 14, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), today announced the submission of a 510(k) to the US Food and Drug Administration for its PulseTx™ System. NPS is a non-thermal drug-free tissue treatment technology that can stimulate unique behaviors in cells by applying ultr... 
Printer Friendly Version
03/01/17Pulse Biosciences to Host Investor Conference Call on March 14, 2017
BURLINGAME, Calif.--(BUSINESS WIRE)--Mar. 1, 2017-- Pulse Biosciences, Inc., (Nasdaq: PLSE) a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), will host its first quarter investor conference call on March 14, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will highlight progress to-date on its NPS clinical programs, PulseTx System development, as well as provide an updat... 
Printer Friendly Version
02/10/17Pulse Biosciences Announces Healthcare Executives and Entrepreneurs Robert Duggan and Dr. Maky Zanganeh Have Acquired a Combined Interest of 17.1% of the Company
Company Appoints Dr. Maky Zanganeh to Company Board of Directors BURLINGAME, Calif.--(BUSINESS WIRE)--Feb. 10, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), today announced that Robert “Bob” Duggan and Maky Zanganeh, the former CEO and COO of Pharmacyclics Inc. (now Pharmacyclics LLC, a wholly owned subsidiary of AbbVie I... 
Printer Friendly Version